2023 Mar 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–.
ABSTRACT
Bumetanide is FDA-approved for managing various edematous conditions secondary to cardiac failure or hepatic or renal disease, including nephrotic syndrome. It is a member of the loop diuretic class of drugs. This activity reviews bumetanide's indications, action, and contraindications as a valuable agent in treating and managing various edematous conditions secondary to cardiac failure or hepatic or renal disease. This activity will highlight the mechanism of action, adverse effects, and other key factors such as dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in the treatment and care of patients with edematous conditions.